MARKET

SLNO

SLNO

SOLENO THERAPEUT
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.070
-0.060
-5.31%
Opening 14:29 05/06 EDT
OPEN
1.120
PREV CLOSE
1.130
HIGH
1.130
LOW
1.030
VOLUME
1.72M
TURNOVER
--
52 WEEK HIGH
4.390
52 WEEK LOW
1.030
MARKET CAP
85.30M
P/E (TTM)
-2.4654
1D
5D
1M
3M
1Y
5Y
Soleno Therapeutics EPS misses by $0.03
Soleno Therapeutics (SLNO): Q1 GAAP EPS of -$0.11 misses by $0.03.Cash and cash equivalents of $41.6MPress Release
Seekingalpha · 21h ago
Soleno Therapeutics Q1 EPS $(0.11) Up From $(0.13) YoY
Soleno Therapeutics (NASDAQ:SLNO) reported quarterly losses of $(0.11) per share. This is a 15.38 percent increase over losses of $(0.13) per share from the same period last year.
Benzinga · 21h ago
10-Q: SOLENO THERAPEUTICS INC
(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operation The interim consolidated financial...
Edgar Online - (EDG = 10Q, 10K) · 22h ago
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results
REDWOOD CITY, May 05, 2021 (GLOBE NEWSWIRE via COMTEX) -- REDWOOD CITY, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno")...
GlobeNewswire · 22h ago
Soleno Therapeutics' DCCR Treatment Shows Improvement In Multiple Behavioral Domains In Prader-Willi Syndrome Patients
Benzinga · 2d ago
Soleno Therapeutics Announces Presentation Of Behavioral Data From Ongoing Extension Study Of DCCR For Treatment Of Prader-Willi Syndrome; Says 'Results Show Improvement in Multiple Behavioral Domains Following Treatment with DCCR'
 Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the presentation of
Benzinga · 2d ago
Soleno Therapeutics Announces Presentation of Positive Behavioral Data from Ongoing Extension Study of DCCR for Treatment of Prader-Willi Syndrome
Results Show Improvement in Multiple Behavioral Domains Following Treatment with DCCR
GlobeNewswire · 2d ago
Prader-Willi Syndrome (PWS) Therapeutics Market to Separate Overstated Growth Through 2021-2025|Says Kenneth Research
May 04, 2021 (AmericaNewsHour) -- Kenneth Research recently added a report on 'Prader-Willi Syndrome (PWS) Therapeutics Market' in its database of market...
AmericaNewsHour · 2d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SLNO. Analyze the recent business situations of SOLENO THERAPEUT through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SLNO stock price target is 7.00 with a high estimate of 8.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 88
Institutional Holdings: 44.94M
% Owned: 56.37%
Shares Outstanding: 79.72M
TypeInstitutionsShares
Increased
22
4.69M
New
10
638.63K
Decreased
20
1.34M
Sold Out
9
3.39M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.19%
Pharmaceuticals & Medical Research
-0.97%
Key Executives
Chairman/Independent Director
Ernest Mario
Chairman/Independent Director
Ernie Mario
President/Chief Executive Officer/Director
Anish Bhatnagar
Chief Financial Officer/Chief Accounting Officer
James Mackaness
Vice President
Patricia Hirano
Vice President
Kristen Yen
Independent Director
William Harris
Independent Director
Gwen Melincoff
Independent Director
Andrew Sinclair
Independent Director
Birgitte Volck
No Data
  • All
  • Financials
  • Insiders
More
About SLNO
Soleno Therapeutics, Inc., formerly Capnia, Inc., is a healthcare company that develops and commercializes neonatology devices and diagnostics. The Company also has a therapeutics platform based on its proprietary technology for precision metering of gas flow. The Company offers products, such as CoSense end-tidal carbon monoxide (ETCO) Monitor, NeoPIP Infant Resuscitator and Accessories, and Serenz Nasal Relief. The Company has developed the CoSense End-Tidal Carbon Monoxide Monitor that measures ETCO for the detection of dangerous hemolysis rates. The Infant Solutions product line, including the NeoPIP Infant Resuscitator Unit and accessories, is designed for controlled and accurate resuscitation of neonates and infants in the clinical environment. Serenz Nasal Relief is a hand-held nasal irrigator that uses carbon dioxide (CO2) gas to wash the nasal passages.

Webull offers kinds of Soleno Therapeutics Inc stock information, including NASDAQ:SLNO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLNO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SLNO stock methods without spending real money on the virtual paper trading platform.